Avalo Therapeutics, Inc. ((AVTX)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avalo Therapeutics, Inc. is conducting a clinical study titled ‘A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS).’ The primary aim is to assess the efficacy and safety of AVTX-009 compared to a placebo in treating patients with moderate to severe Hidradenitis Suppurativa, a chronic skin condition.
The study is testing two experimental regimens of the drug AVTX-009, administered as subcutaneous injections either every two or four weeks, against a placebo. The goal is to determine the potential benefits of AVTX-009 in managing symptoms of Hidradenitis Suppurativa.
This interventional study is designed with a randomized, parallel-group model and employs double masking, meaning both participants and investigators are unaware of the treatment allocations. The primary purpose of the study is treatment-focused, aiming to provide new therapeutic options for patients.
The study began on September 17, 2024, with a recent update on September 3, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is essential for stakeholders tracking the development timeline.
The outcome of this study could significantly impact Avalo Therapeutics’ market position, potentially boosting investor confidence if results are positive. The success of AVTX-009 could also influence the competitive landscape in the treatment of Hidradenitis Suppurativa, where few effective therapies currently exist.
The study is ongoing, with further details available on the ClinicalTrials portal.